Health  Vol.6 No.12 , June 2014
Minigene Analysis of the c.743 + 40A > G Intronic Variant in the CFTR Gene
Abstract: Background: Since the identification of the cystic fibrosis transmembrane regulator (CFTR) gene in 1989, many polymorphisms have been identified in cystic fibrosis (CF) or CFTR-related disorders (CFTR-RDs) patients and still remain to be characterized at the molecular level. These polymorphisms are difficult to classify as pathogenic or non-disease causing because the polymorphisms are either located in the coding region, but are synonymous, or are found in the intronic regions. Here we investigated the potential impact of the c.743 + 40A > G polymorphism within CFTR intron 6 on the alternative splicing. Indeed, this variant has been observed frequently in our examined patients. Moreover, a family carrying this variant exhibited CFTR-RD phenotype. Methods: By denaturing high pressure liquid phase chromatography (DHPLC) and sequencing, thirty of 293 subjects French origin carried the c.743 + 40A > G variant. Of these, 16 patients were affected by CF or CFTR-RD. Wild-type sequences and mutant CFTR intron 6 and its boundaries were inserted into the pTBNdeI hybride minigene and expressed in three different cell lines. After RT-PCR analysis of mRNA using specific primers, sequences of the minigene transcripts were obtained. Results: No aberrant splicing was detected with minigene carrying c.743 + 40A > G variant in all transfected cell lines. However, an alternative splicing in the positive control was detected with a minigene carrying the c.1392G > T + 1G > T mutation: 5 nucleotides were deleted from mRNA sequences, indicating that used cell lines are appropriate for studying the splicing. Conclusion: Transient transfections of a minigene containing the c.743 + 40A > G polymorphism showed no splicing errors, and thus this intronic alteration was finally classified as non-pathogenic. As it is always associated with c.2562T > G and c.4389G > A, or TG12-7T poly-morphisms, further experiments are needed to determine the role of these complex alleles in disease pathogenesis.
Cite this paper: El-Seedy, A. , Farhat, R. , Pasquet, M. , Kitzis, A. and Ladeveze, V. (2014) Minigene Analysis of the c.743 + 40A > G Intronic Variant in the CFTR Gene. Health, 6, 1352-1360. doi: 10.4236/health.2014.612166.


[2]   Wang, D. and Sadée, W. (2006) Searching for Polymorphisms That Affect Gene Expression and mRNA Processing: Example ABCB1 (MDR1). Journal of the American Association of Pharmaceutical Scientists (AAPS), 8, 515-520.

[3]   Nielsen, K.B., Sørensen, S., Cartegni, L., Corydon, T.J., Doktor, T.K., Schroeder, L.D., Reinert, L.S., Elpeleg, O., Krainer, A.R., Gregersen, N., Kjems, J. and Andresen, B.S. (2007) Seemingly Neutral Polymorphic Variants May Confer Immunity to Splicing-Inactivating Mutations: A Synonymous SNP in Exon 5 of MCAD Protects from Deleterious Mutations in a Flanking Exonic Splicing Enhancer. American Journal of Human Genetics, 80, 416-432.

[4]   Cuppens, H., Lin, W., Jaspers, M., Costes, B., Teng, H., Vankeerberghen, A., Jorissen, M., Droogmans, G., Reynaert, I., Goossens, M., Nilius, B. and Cassiman, J.J. (1998) Polyvariant Mutant Cystic Fibrosis Transmembrane Conductance Regulator Genes. The Polymorphic (TG)m Locus Explains the Partial Penetrance of the T5 Polymorphism as a Disease Mutation. Journal of Clinical Investigation, 101, 487-496.

[5]   Steiner, B., Truninger, K., Sanz J., Schalle, R.A. and Gallati, S. (2004) The Role of Common Single-Nucleotide Polymorphisms on Exon 9 and Exon 12 Skipping in Nonmutated CFTR alleles. Human Mutation, 24, 120-129.

[6]   Chu, C.S., Trapnell, B.C., Curristin, S., Cutting, G.R. and Crystal, R.G. (1993) Genetic Basis of variable Exon 9 Skipping in Cystic Fibrosis Transmembrane Conductance Regulator mRNA. Nature Genetics, 3, 151-156.

[7]   Bombieri, C., Giorgi, S., Carles, S., De Cid, R., Belpinati, F., Tandoi, C., Pallares-Ruiz, C., Lazaro, C., Ciminelli, B.M., Romey, M.C., Casals, T., Pompei, F., Gandini, G., Claustres, M., Estivill, X., Pignatti, P.F. and Modiano, G. (2000) A New Approach for Identifying Non-Pathogenic Mutations: An Analysis of the Cystic Fibrosis Transmembrane Regulator Gene in Normal Individuals. Human Genetics, 106, 172-178.

[8]   Luzardo, G., Aznarez, I., Crispino, B., Mimbacas, A., Martínez, L., Poggio, R., Zielenski, J., Tsui, L.C. and Cardoso, H. (2002) Cystic Fibrosis in Uruguay. Genetics and Molecular Research, 1, 32-38.

[9]   Kolesar, P., Minarik, G., Baldovic, M., Ficek, A., Kovacs, L. and Kadasi, L. (2008) Mutation Analysis of the CFTR Gene in Slovac Cystic Fibrosis Patients by DHPLC and Sequencing: Identification of Four Novel Mutations. General Physiology and Biophysics, 27, 299-305.

[10]   Loumia, O., Ferec, C., Mercier, B., Creff, J., Fercot, B., Denine, R. and Grangaud, J.P. (2008) CFTR Mutations in the Algerian Population. Journal of Cystic Fibrosis, 7, 54-59.

[11]   Casals, T., Bassas, L., Egozcue, S., Ramos, M.D., Giménez, J., Segura, A., Garcia, F., Carrera, M., Larriba, A., Sarquella, J. and Estivill, X. (2000) Heterogeneity for Mutations in the CFTR Gene and Clinical Correlations in Patients with Congenital Absence of the vas Deferens. Human Reproduction, 15, 1476-1483.

[12]   Fanen, P., Ghanem, N., Vidaud, M., Besmond, C., Martin, J., Costes, B., Plassa, F. and Goossens, M. (1992) Molecular Characterization of Cystic Fibrosis: 16 Novel Mutations Identified by Analysis of the Whole Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Coding Regions and Splice Site Junctions. Genomics, 13, 770-776.

[13]   Le Marechal, C., Audrezet, MP., Quere, I., Raquenes, O., Langonne ,S. and Ferec, C. (2001) Complete and Rapid Scanning of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene by Denaturing High-Performance Liquid Chromatography (D-HPLC): Major Implications for Genetic Counselling. Human Genetics, 108, 290-298.

[14]   Pagani, F., Buratti, E., Stuani, C., Romano, M., Zuccato, E., Niksic, M., Giglio, L., Faraguna, D. and Baralle, F.E. (2000) Splicing Factors Induce Cystic Fibrosis Transmembrane Regulator Exon 9 Skipping through a Non Evolutionary Conserved Intronic Element. Journal of Biological Chemistry, 275, 21041-21047.

[15]   Faa, V., Incani, F., Meloni, C.D., Masala, M., Baffico, A.M., Seia, M., Cao, A. and Rosatelli, M.C. (2009) Characterization of a Disease-associated Mutation Affecting a Putative Splicing Regulatory Element in Intron 6b of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene. Journal of Biological Chemistry, 284, 30024-30031.

[16]   Janssen, R., Kruit, A., Grutters, J.C., Ruven, H.J.T., van Moorsel, C.M.H. and van den Bosch, J.M.M. (2005) TIMP-3 Promoter Gene Polymorphisms in BFL. Thorax, 60, 974-975.

[17]   Davies, J., Alton, E. and Griesenbach, U. (2005) Cystic Fibrosis Modifier Genes. Journal of the Royal Society of Medicine, 45, 47-54.

[18]   Pagani, F., Stuani, C., Tzetis, M., Kanavakis, E., Efthymiadou, A., Doudounakis, S., Casals, T. and Baralle, F.E. (2003) New Type of Disease Causing Mutations: The Example of the Composite Exonic Regulatory Elements of Splicing in CFTR Exon 12. Human Molecular Genetics, 12, 1111-1120.

[19]   Desmet, F.-O., Hamroun, D., Lalande, M., Collod-Béroud, G., Claustres, M. and Béroud, C. (2009) Human Splicing Finder: An Online Bioinformatics Tool to Predict Splicing Signals. Nucleic Acids Research, 37, 215-220.